PHENTrials.com

Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

Find Your Trial

PHEN’s “Find Your Trial (FYT)” search tool connects patients with prostate cancer clinical trials with where you are on your prostate cancer journey.  Select your diagnosis below.

Low Risk

Intermediate Risk

High Risk

Cancer Recurrence

Non-Metastatic Castration Resistant

Metastatic Castration Sensitive

Metastatic Castration Resistant

Our Partners

For Partnership Interest

AMG509 Patient Summary

This clinical trial is for patients who have metastatic castration resistant prostate cancer (mCRPC) and failed to respond to abiraterone acetate or enzalutamide (but not both) and to taxane-based chemotherapy.

Prostate Health

Lorikeet Patient Summary

Lorigerlimab is an investigational drug being tested in clinical trials. It is designed to block two checkpoints, telling the immune system cells to wake up and start killing cancer cells. Checkpoint inhibitors, including lorigerlimab, may cause side effects.

Prostate Health

Libertas Patient Summary

The LIBERTAS STUDY is researching a way to potentially treat a type of prostate cancer that still responds to hormone therapy. Prostate cancer that spreads to other parts of the body but can still be controlled by interfering with the hormone function of the cancer is called metastatic castration-sensitive prostate cancer (mCSPC).

Prostate Health

MEVPRO-1 Patient Summary

The primary objective of this clinical trial is to assess the efficacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC), which will be compared to standard treatments alone (either enzalutamide or docetaxel).

Prostate Health

Omaha-003 Patient Summary

This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer. 

Prostate Health

Omaha-004 Patient Summary

This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose cancer progressed on or after they were previously treated with next-generation Hormonal Agent (NHA). 

This information is for educational purposes only and not intended as medical advice.
Patients should consult their medical doctor for advice and recommendations about specific clinical trials.

Pin It on Pinterest